This short book brings together novel cross-interdisciplinary investigation from both natural and social science, representing a true hybrid across disciplines examining the 'politics' and 'science' of COVID-19. Viruses, Vaccines, and Antivirals: Why Politics Matters considers the dynamics surrounding viruses, proposed vaccines, and antiviral therapies, contextualizing what governments have done during the COVID-19 crisis. The four basic phases of a pandemic are considered with a strong focus on COVID-19, namely the anticipating and early virus detection, containment strategies, policies to control and mitigate the spread of the virus and policies aimed at opening up society. Viruses, Vaccines, and Antivirals: Why Politics Matters examines policy developments throughout these phases in key nations worldwide and puts forward a blueprint for countries developing public policies to deal with a pandemic.

The Vaccine Book, Second Edition provides comprehensive information on the current and future state of vaccines. It reveals the scientific opportunities and potential impact of vaccines, including economic and ethical challenges, problems encountered when producing vaccines, how clinical vaccine trials are designed, and how to introduce vaccines into widespread use. Although vaccines are now available for many diseases, there are still challenges ahead for major diseases, such as AIDS, tuberculosis, and malaria. This book is designed for students, researchers, public health officials, and all others interested in increasing their understanding of vaccines. It answers common questions regarding the use of vaccines in the context of a rapidly expanding anti-vaccine environment. This new edition is completely updated and revised with new and unique topics, including new vaccines, problems of declining immunization rates, trust in vaccines, the vaccine hesitancy, and the social value of vaccines for the community vs. the individual child's risk. - Provides insights into diseases that could be prevented, along with the challenges facing research scientists in the world of vaccines - Gives new ideas about future vaccines and concepts - Introduces new vaccines and concepts - Gives ideas about challenges facing public and private industrial investors in the vaccine area - Discusses the problem of declining immunization rates and vaccine hesitancy

This comprehensive account of the human herpesviruses provides an encyclopedic overview of their basic virology and clinical manifestations. This group of viruses includes human simplex type 1 and 2, Epstein–Barr virus, Kaposi's Sarcoma-associated herpesvirus, cytomegalovirus, HHV6A, 6B and 7, and varicella-zoster virus. The viral diseases and cancers they cause are significant and often recurrent. Their prevalence in the developed world accounts for a major burden of disease, and as a result there is a great deal of research into the pathophysiology of infection and immunobiology. Another important area covered within this volume concerns antiviral therapy and the development of vaccines. All these aspects are covered in depth, both scientifically and in terms of clinical guidelines for patient care. The text is illustrated generously throughout and is fully referenced to the latest research and developments.

This book is a collection of chapters dealing with examples of RNA and DNA viruses, and issues such as how these gene packages have learnt to take advantage of their hosts, molecular recognition events that hosts may use to counterattack the viruses, and how researchers have developed strategies to use viruses or their parts as tools for different purposes.

This short book brings together novel cross-interdisciplinary investigation from both natural and social science, representing a true hybrid across disciplines examining the ‘politics’ and ‘science’ of COVID-19. Viruses, Vaccines, and Antivirals: Why Politics Matters considers the dynamics surrounding viruses, proposed vaccines, and antiviral therapies, contextualizing what governments have done during the COVID-19 crisis. The four basic phases of a pandemic are considered with a strong focus on COVID-19, namely the anticipating and early virus detection, containment strategies, policies to control and mitigate the spread of the virus and policies aimed at opening up society. Viruses, Vaccines, and Antivirals: Why Politics Matters examines policy developments throughout these phases in key nations worldwide and puts forward a blueprint for countries developing public policies to deal with a pandemic.

Considerable advances have been made in the treatment of antiviral diseases over the last decade. Several new drugs have been introduced while new clinical information has been gathered on the efficacy of existing drugs. This study aims to provide an examination of the basic science (drug formulae, structure and biochemical activity) and clinical information (usage and efficacy) on chemotherapy, as well as describing future potentials.

Biomedical Innovations to Combat COVID-19 provides an updated overview on the development of vaccines, antiviral drugs and nanomaterials, and diagnostic methods for the fight against COVID-19. Perspectives on such technologies are identified, discussed, and enriched with figures for easy understanding and applicability. Furthermore, it contains basic aspects of virology, immunology, and antiviral drugs that are needed to fully appreciate these innovations. This book is split into four sections: introduction, presenting basic virologic and epidemiological aspects of COVID-19; vaccines against COVID-19, discussing their different types and applications used to develop them; diagnostic approaches for SARS-CoV-2, encompassing advanced sensing and microfluidic-based biosensors; and drug development and delivery, where antivirals based on nanomaterials or drugs are presented. It is a valuable source for virologists, biotechnologists, and members of biomedical field interested in learning more about how novel technologies can be applied to fasten the eradication of the COVID-19 and similar pandemics. - Presents updated literature coverage summarizing the most relevant information on COVID-19 - Written by experts from diverse scientific domains in order to provide readers with a thorough view on the subject - Encompasses tables, figures and information trees especially developed for the book in order to condense and highlight key points for quick reference

Discusses how to fight Ebola, SARS Corona, and other known or emerging human viruses by building on the successes in antiviral therapy of the past decades Written by leading medicinal chemists from academia and industry, this book discusses the entire field of antiviral drug discovery and development from a medicinal chemistry perspective, focusing on antiviral drugs, targets, and viral disease mechanisms. It provides an outlook on emerging pathogens such as Ebola, Zika, West Nile, Lassa, and includes a chapter on SARS Coronoavirus-2 causing the present pandemic. New Drug Development for Known and Emerging Viruses describes the discovery and development process for antiviral agents for different classes of viruses and targets based on the experiences from the nine human viruses for which approved drugs are on the market (HIV, HCV, Influenza, RSV, HBV, HPV, HCMV, HSV, and VZV). It covers the properties and potential of 20 classes of currently approved antivirals, including combination drugs, and looks at novel antiviral strategies against emerging viruses. Covers the entire field of antiviral drug discovery and development Addresses the need for antiviral drugs to combat major health threats such as Ebola, Zika, West Nile, and SARS Coronavirus-2 Summarizes the successes of the past 15 years in developing ground-breaking medicines against 9 major human viruses, both from the medicinal chemistry and the pharmacological angle Discusses practical and strategic challenges in the drug discovery and development process, including screening technologies, latency, and toxicity issues New Developments in Antiviral Drugs is an important book for medicinal chemists, pharmaceutical chemists, virologists, and epidemiologists, and will be of great interest to those in the ;pharmaceutical industry and public health agencies.

In March and early April 2009, a new, swine-origin 2009-H1N1 influenza A virus emerged in Mexico and the United States. During the first few weeks of surveillance, the virus spread by human-to-human transmission worldwide to over 30 countries. On June 11, 2009, the World Health Organization (WHO) raised the worldwide pandemic alert level to Phase 6 in response to the ongoing global spread of the novel influenza A (H1N1) virus. By October 30, 2009, the H1N1 influenza A had spread to 191 countries and resulted in 5,700 fatalities. A national emergency was declared in the United States and the swine flu joined SARS and the avian flu as pandemics of the 21st century. Vaccination is currently available, but in limited supply, and with a 60 percent effectiveness rate against the virus. The story of how this new influenza virus spread out of Mexico to other parts of North America and then on to Europe, the Far East, and now Australia and the Pacific Rim countries has its origins in the global interconnectedness of travel, trade, and tourism. Given the rapid spread of the virus, the international scientific, public health, security, and policy communities had to mobilize quickly to characterize this unique virus and address its potential effects. The World Health Organization and Centers for Disease Control have played critical roles in the surveillance, detection and responses to the H1N1 virus. The Domestic and International Impacts of the 2009-H1N1 Influenza A Pandemic: Global Challenges, Global Solutions aimed to examine the evolutionary origins of the H1N1 virus and evaluate its potential public health and socioeconomic consequences, while monitoring and mitigating the impact of a fast-moving pandemic. The rapporteurs for this workshop reported on the need for increased and geographically robust global influenza vaccine production capacities; enhanced and sustained interpandemic demand for seasonal influenza vaccines; clear "triggers" for pandemic alert levels; and accelerated research collaboration on new vaccine manufacturing techniques. This book will be an essential guide for healthcare professionals, policymakers, drug manufacturers and investigators.

Essential Human Virology, Second Edition focuses on the structure and classification of viruses, virus transmission and virus replication strategies based upon type of viral nucleic acid. Several chapters focus on notable and recognizable viruses and the diseases caused by them, including influenza, HIV, hepatitis viruses, poliovirus, herpesviruses and emerging and dangerous viruses. Additionally, how viruses cause disease (pathogenesis) is highlighted, along with discussions on immune response to viruses, vaccines, anti-viral drugs, gene therapy, the beneficial uses of viruses, research laboratory assays and viral diagnosis assays. Fully revised and updated with new chapters on coronaviruses, nonliving infectious agents, and notable non-human viruses, the book provides students with a solid foundation in virology. - Focuses on human diseases and the cellular pathology that viruses cause - Highlights current and cutting-edge technology and associated issues - Presents real case studies and current news highlights in each chapter - Features dynamic illustrations, chapter assessment questions, key terms, and a summary of concepts, as well as an instructor website with lecture slides, a test bank and recommended activities - Updated and revised, with new chapters on coronaviruses, nonliving infectious agents, and notable non-human viruses